Otovel Ear Drops

Name: Otovel Ear Drops

Indications and Usage for Otovel Ear Drops

OTOVEL is indicated for the treatment of acute otitis media with tympanostomy tubes (AOMT) in pediatric patients (aged 6 months and older) due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Pseudomonas aeruginosa.


OTOVEL is contraindicated in:

  • Patients with known hypersensitivity to fluocinolone acetonide or other corticosteroids, ciprofloxacin or other quinolones, or to any other components of OTOVEL.
  • Viral infections of the external ear canal, including varicella and herpes simplex infections and fungal otic infections.

Adverse Reactions

The following serious adverse reactions are described elsewhere in the labeling:

Hypersensitivity Reactions [see Warnings and Precautions (5.1)]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In clinical trials, 224 patients with AOMT were treated with OTOVEL for a median duration of 7 days. All the patients received at least one dose of OTOVEL. There were 220 patients who received at least one dose of ciprofloxacin (CIPRO) and 213 patients received at least one dose of fluocinolone acetonide (FLUO).

The most common adverse reactions that occurred in 1 or more patients are as follows:

Table 1: Selected Adverse Reactions that Occurred in 1 or more Patients in the OTOVEL Group

Adverse Reactions1

Number (%) of Patients








12 (5.4%)

9 (4.1%)

12 (5.6%)

Excessive granulation tissue

3 (1.3%)

0 (0.0%)

2 (0.9%)

Ear infection

2 (0.9%)

3 (1.4%)

1 (0.5%)

Ear pruritus

2 (0.9%)

1 (0.5%)

1 (0.5%)

Tympanic membrane disorder

2 (0.9%)

0 (0.0%)

0 (0.0%)

Auricular swelling

1 (0.4%)

1 (0.5%)

0 (0.0%)

Balance disorder

1 (0.4%)

0 (0.0%)

0 (0.0%)

1Selected adverse reactions that occurred in ≥ 1 patient in the OTOVEL group derived from all reported adverse events that could be related to the study drug or the drug class.

Postmarketing Experience

The following adverse reactions have been identified during postapproval use of ciprofloxacin and fluocinolone acetonide otic solution, 0.3% / 0.025% outside the US. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

  • Immune system disorders: allergic reaction.
  • Infections and infestations: candidiasis.
  • Nervous system disorders: dysgeusia, paresthesia (tingling in ears), dizziness, headache.
  • Ear and labyrinth disorders: ear discomfort, hypoacusis, tinnitus, ear congestion.
  • Vascular disorders: flushing.
  • Skin and subcutaneous tissue disorders: skin exfoliation.
  • Injury, poisoning and procedural complications: device occlusion (tympanostomy tube obstruction).


Due to the characteristics of this preparation, no toxic effects are to be expected with an otic overdose of OTOVEL.

How Supplied/Storage and Handling

How supplied

OTOVEL (ciprofloxacin and fluocinolone acetonide) otic solution, 0.3 %/0.025 %, is a sterile, preservative-free, clear otic solution supplied in blue translucent single-dose 0.25 mL vials. Fourteen single-dose vials are packaged in a protective foil pouch contained in a carton (NDC 24338-080-14).


Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Protect from light; store unused vials in pouch and discard 7 days after opening the pouch. Do not open until ready to use. Discard vial after use.

PATIENT INFORMATION OTOVEL (OH-toe-vel) (ciprofloxacin and fluocinolone acetonide) otic solution

What is OTOVEL?

OTOVEL is a prescription medicine used in the ear only (otic use) that contains 2 medicines, a quinolone antibiotic medicine called ciprofloxacin and a corticosteroid medicine called fluocinolone acetonide. OTOVEL is used in children 6 months of age and older to treat a type of middle ear infection called acute otitis media with tympanostomy tubes (AOMT) in children who have a tube in their eardrum known as a tympanostomy tube, to prevent having too much fluid in the middle ear.

It is not known if OTOVEL is safe and effective in children under 6 months of age.

Who should not use OTOVEL?

Do not use OTOVEL if you:

  • Are allergic to ciprofloxacin, quinolones, fluocinolone acetonide, corticosteroids or any of the ingredients in OTOVEL. See the end of this Patient Information leaflet for a complete list of ingredients in OTOVEL.
  • Have an outer ear canal infection caused by certain viruses including chicken pox (varicella) and the herpes simplex virus,
  • Have an ear infection caused by a fungus.

What should I tell my healthcare provider before using OTOVEL?

Before using OTOVEL, tell your healthcare provider about all of your medical conditions, including if you:

  • Are pregnant or plan to become pregnant, although OTOVEL is not expected to harm your baby.
  • Are breastfeeding or plan to breastfeed, although OTOVEL is not expected to pass into your breast milk and to harm your baby.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I use OTOVEL?

  • Read the detailed Instructions for Use that come with OTOVEL.
  • Use OTOVEL exactly as your healthcare provider tells you to use it.
  • OTOVEL is for use in the ear only (otic use). Do not inject OTOVEL or use OTOVEL in the eye.
  • OTOVEL comes as a liquid in single-dose vials.
  • Apply the entire dose of OTOVEL from 1 of the single-dose vials, into the affected ear 2 times a day (for a total of 2 single-dose vials a day) for 7 days. Each dose should be about 12 hours apart.

If your symptoms do not improve after 7 days of treatment with OTOVEL, call your healthcare provider.

  • Call your healthcare provider right away if:
    • you have fluid that continues to drain from your ear (otorrhea) after you have finished your treatment with OTOVEL,
    • you have fluid that drains from your ear 2 or more times within 6 months after you stop treatment with OTOVEL.

What are the possible side effects of OTOVEL?

OTOVEL may cause serious side effects, including:

  • Allergic reactions. Stop using OTOVEL and call your healthcare provider if you have any of the following signs or symptoms of an allergic reaction:
  • hives (urticaria)
  • swelling of your face, lips, mouth, or tongue
  • rash
  • itching
  • trouble breathing
  • dizziness, fast heartbeat, or pounding in your chest

The most common side effects that occurred during the testing of OTOVEL include:

  • fluid that continues to drain from your ear (otorrhea)
  • extra tissue that grows on a part of the ear that has been injured (excessive granulation tissue)
  • ear pain
  • ear infection
  • ear itching (pruritus)
  • swelling of the outer or inside part of the ear
  • balance problems

If an allergic reaction to OTOVEL occurs, stop using the product and contact your doctor.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of OTOVEL. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store OTOVEL?

  • Store unopened OTOVEL vials in the protective foil pouch they come in.
  • Store OTOVEL at 20°-25°C (68°-77°F).
  • Keep OTOVEL out of light.
  • Do not open the OTOVEL foil pouch until ready to use.
  • When the OTOVEL foil pouch is opened, use the vials within 7 days.
  • When an OTOVEL vial is opened, use it right away.

Keep OTOVEL and all medicines out of the reach of children.

General information about the safe and effective use of OTOVEL.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use OTOVEL for a condition for which it was not prescribed. Do not give OTOVEL to other people, even if they have the same symptoms that you have. It may harm them.

This Patient Information leaflet summarizes the most important information about OTOVEL. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about OTOVEL that is written for healthcare professionals.

What are the ingredients in OTOVEL?

Active ingredients: ciprofloxacin and fluocinolone acetonide.

Inactive ingredients: polysorbate, povidone, glycerin, and water.

Distributed by: Arbor Pharmaceuticals, LLC., Atlanta, GA 30328.

Under license of Laboratorios SALVAT, S.A. OTOVEL is a registered trademark of Laboratorios SALVAT, S.A.

For more information, go to www.arborpharma.com or call 1-866-516-4950.

This Patient Information has been approved by the U.S. Food and Drug Administration Issued: 4/2016